Cho E Y, Choi Y L, Chae S W, Sohn J H, Ahn G H
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, Korea.
Int J Gynecol Cancer. 2006 May-Jun;16(3):1000-6. doi: 10.1111/j.1525-1438.2006.00553.x.
We studied the immunoexpression of p14ARF, MDM2, and p53, in addition to relationships between those protein expressions and estrogen receptor (ER)alpha in ovarian serous tumors including benign (n= 23), borderline (n= 41), and malignant (n= 94). The aberrant expressions of p14ARF, MDM2, and p53 were observed in 19.6% (31/158), 47.5% (75/158), and 39.9% (63/158) of cases, respectively. The expression of MDM2 was significantly higher in borderline tumors compared to benign (P= 0.04) and malignant (P < 0.01) tumors. p53 expression in borderline tumors was uncommon, and p14ARF expression loss was mainly observed in carcinomas. Altered expression of p14ARF, MDM2, and p53 shows significant relationship with stage. Overexpression of MDM2 (P= 0.01) and loss of p14ARF expression (P= 0.04) were significantly associated with ER expression. Our results suggest that alteration of p14ARF-MDM2-p53 pathway proteins may contribute significantly to the tumorigenesis of ovarian serous neoplasms, and ER is involved in cellular regulation of p14ARF-MDM2-p53 pathway in ovarian serous neoplasms.
我们研究了p14ARF、MDM2和p53的免疫表达，以及这些蛋白表达与卵巢浆液性肿瘤中雌激素受体（ER）α之间的关系，这些肿瘤包括良性（n = 23）、交界性（n = 41）和恶性（n = 94）肿瘤。分别在19.6%（31/158）、47.5%（75/158）和39.9%（63/158）的病例中观察到p14ARF、MDM2和p53的异常表达。与良性肿瘤（P = 0.04）和恶性肿瘤（P < 0.01）相比，MDM2在交界性肿瘤中的表达显著更高。交界性肿瘤中p53表达不常见，p14ARF表达缺失主要见于癌。p14ARF、MDM2和p53的表达改变与分期显著相关。MDM2的过表达（P = 0.01）和p14ARF表达的缺失（P = 0.04）与ER表达显著相关。我们的结果表明，p14ARF-MDM2-p53通路蛋白的改变可能对卵巢浆液性肿瘤的发生发展有显著贡献，并且ER参与卵巢浆液性肿瘤中p14ARF-MDM2-p53通路的细胞调控。
